Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology company focused on developing therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). The company is known for its innovative gene therapy, Elevidys, which has been approved for treating DMD. Sarepta's competitors include companies like Pfizer and Roche, which are also working on treatments for muscular dystrophy.
On July 17, 2025, William Blair updated the grade for NASDAQ:SRPT to "Market Perform," maintaining a "hold" action. At the time, the stock price was approximately $21.98. This announcement came as Sarepta was undergoing a reorganization, which has bolstered investor confidence, as highlighted by Benzinga. The reorganization is part of Sarepta's efforts to strengthen its position in the biotechnology sector.
Sarepta's stock price has seen a rise following an after-hours update regarding Elevidys. The company is working on expanding the label for Elevidys, and the FDA has requested a black box warning for acute liver injury and failure. Sarepta has agreed to this change, addressing significant issues with the ambulant portion of the Elevidys label. This move is likely to reassure investors about the company's commitment to safety.
In June, Sarepta temporarily halted shipments of Elevidys for non-ambulatory patients. A committee within the company is reviewing cases of acute liver failure and considering additional immunosuppression regimens. They have agreed on an enhanced regimen using sirolimus for non-ambulant patients. Sarepta plans to submit these findings to the FDA for further discussion, which could impact future stock performance.
Currently, NASDAQ:SRPT is priced at $21.98, reflecting a 19.59% increase with a change of $3.60. The stock has fluctuated between $20.94 and $22.86 today. Over the past year, it reached a high of $153.30 and a low of $16.88. With a market capitalization of approximately $2.16 billion and a trading volume of 19,634,197 shares, Sarepta remains a significant player on the NASDAQ exchange.
